Pfizer Inc (PFE)
27.78
+0.19
(+0.69%)
USD |
NYSE |
Mar 27, 16:00
27.82
+0.04
(+0.14%)
Pre-Market: 06:56
Pfizer Accounts Receivable (Quarterly): 11.18B for Dec. 31, 2023
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 11.18B |
September 30, 2023 | 11.09B |
June 30, 2023 | 10.23B |
March 31, 2023 | 12.30B |
December 31, 2022 | 10.95B |
September 30, 2022 | 16.08B |
June 30, 2022 | 15.16B |
March 31, 2022 | 13.22B |
December 31, 2021 | 11.48B |
September 30, 2021 | 11.90B |
June 30, 2021 | 10.59B |
March 31, 2021 | 9.864B |
December 31, 2020 | 7.913B |
September 30, 2020 | 10.01B |
June 30, 2020 | 9.128B |
March 31, 2020 | 9.881B |
December 31, 2019 | 6.772B |
September 30, 2019 | 9.439B |
June 30, 2019 | 9.793B |
March 31, 2019 | 9.599B |
December 31, 2018 | 8.025B |
September 30, 2018 | 10.02B |
June 30, 2018 | 9.873B |
March 31, 2018 | 9.452B |
December 31, 2017 | 8.221B |
Date | Value |
---|---|
September 30, 2017 | 10.00B |
June 30, 2017 | 9.476B |
March 31, 2017 | 8.892B |
December 31, 2016 | 8.225B |
September 30, 2016 | 9.836B |
June 30, 2016 | 9.138B |
March 31, 2016 | 9.033B |
December 31, 2015 | 8.176B |
September 30, 2015 | 9.535B |
June 30, 2015 | 8.951B |
March 31, 2015 | 8.92B |
December 31, 2014 | 8.401B |
September 30, 2014 | 9.955B |
June 30, 2014 | 10.39B |
March 31, 2014 | 9.399B |
December 31, 2013 | 9.357B |
September 30, 2013 | 11.37B |
June 30, 2013 | 11.52B |
March 31, 2013 | 12.74B |
December 31, 2012 | 10.68B |
September 30, 2012 | 12.52B |
June 30, 2012 | 12.88B |
March 31, 2012 | 14.18B |
December 31, 2011 | 13.06B |
September 30, 2011 | 15.75B |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
6.772B
Minimum
Dec 2019
16.08B
Maximum
Sep 2022
10.83B
Average
10.41B
Median
Accounts Receivable (Quarterly) Benchmarks
Amgen Inc | 7.268B |
Gilead Sciences Inc | 4.66B |
Johnson & Johnson | 14.87B |
Viking Therapeutics Inc | -- |
Moderna Inc | 892.00M |